NCT05877599 - A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | Biotech Hunter

Enrollment

162

Participants

Timeline

Start Date

July 12, 2023

Primary Completion Date

September 1, 2028

Study Completion Date

August 1, 2039

Conditions

Non-small Cell Lung CancerHead and Neck Squamous Cell CarcinomaColorectal CarcinomaPancreatic AdenocarcinomaBreast CancerOther Solid TumorsOvarian Cancer

Interventions

BIOLOGICAL

Autologous, engineered T Cells targeting TP53 R175H

"* Pre-conditioning by non-myeloablative chemotherapy with fludarabine and cyclophosphamide~* Single infusion TCR T cells~* Post-infusion recombinant interleukin-2 (rIL-2)"

Trial Locations (18)

10065

RECRUITING

Research Site, New York

15232

RECRUITING

Research Site, Pittsburgh

27103

SUSPENDED

Research Site, Winston-Salem

28204

SUSPENDED

Research Site, Charlotte

32224

RECRUITING

Research Site, Jacksonville

33136

SUSPENDED

Research Site, Miami

33612

SUSPENDED

Research Site, Tampa

37203

RECRUITING

Research Site, Nashville

53226

RECRUITING

Research Site, Milwaukee

77030

RECRUITING

Research Site, Houston

78665

RECRUITING

Research Site, Round Rock

85234

RECRUITING

Research Site, Gilbert

90404

RECRUITING

Research Site, Santa Monica

91010

RECRUITING

Research Site, Duarte

92663

RECRUITING

Research Site, Newport Beach

97213

RECRUITING

Research Site, Portland

02115

RECRUITING

Research Site, Boston

08901

RECRUITING

Research Site, New Brunswick